Forty Seven (FTSV) Given a $21.00 Price Target at HC Wainwright

HC Wainwright set a $21.00 price target on Forty Seven (NASDAQ:FTSV) in a report issued on Tuesday, TipRanks reports. The brokerage currently has a buy rating on the stock.

FTSV has been the subject of a number of other reports. Zacks Investment Research raised Forty Seven from a hold rating to a buy rating and set a $20.00 price target for the company in a report on Wednesday, May 8th. FIG Partners began coverage on Forty Seven in a research note on Friday, February 1st. They set a buy rating and a $30.00 target price for the company. Oppenheimer reaffirmed a buy rating on shares of Forty Seven in a research note on Tuesday, March 19th. Finally, Guggenheim began coverage on Forty Seven in a research note on Friday, April 12th. They set a buy rating for the company. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $26.75.

Shares of NASDAQ:FTSV opened at $12.04 on Tuesday. Forty Seven has a 12-month low of $10.50 and a 12-month high of $23.83.

Forty Seven (NASDAQ:FTSV) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.14). On average, equities research analysts anticipate that Forty Seven will post -2.85 EPS for the current fiscal year.

In related news, Director Ravindra Majeti sold 4,311 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $16.02, for a total value of $69,062.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Anthony Mccamish sold 16,500 shares of the stock in a transaction on Wednesday, February 20th. The shares were sold at an average price of $14.99, for a total value of $247,335.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 196,195 shares of company stock valued at $3,417,432. Corporate insiders own 37.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of FTSV. MetLife Investment Advisors LLC acquired a new stake in shares of Forty Seven during the 1st quarter worth about $122,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Forty Seven during the 1st quarter worth about $88,000. Goldman Sachs Group Inc. raised its position in shares of Forty Seven by 42.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 178,359 shares of the company’s stock worth $2,882,000 after acquiring an additional 53,498 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Forty Seven by 68.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 32,032 shares of the company’s stock worth $518,000 after acquiring an additional 12,982 shares in the last quarter. Finally, Altrinsic Global Advisors LLC acquired a new stake in shares of Forty Seven during the 1st quarter worth about $355,000. 43.70% of the stock is owned by hedge funds and other institutional investors.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Featured Story: Investing in Growth Stocks

Analyst Recommendations for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.